SOCIAL AND PSYCHOLOGICAL EFFECTS OF OZEMPIC USE IN CLINICAL PRACTICE
Keywords:
semaglutide, Ozempic, GLP-1 receptor agonists, weight stigma, body image, eating disorders, mental health, clinical practiceAbstract
Glucagon-like peptide-1 (GLP-1) receptor agonists, and semaglutide (Ozempic) in particular, have become an effective treatment for type 2 diabetes and obesity. Their use now extends well beyond strict medical indications: a considerable share is driven by the wish to improve appearance and often takes place without medical supervision. This review aims to present to clinicians the social and psychological consequences of these drugs, based on peerreviewed publications indexed in PubMed.
The drugs also act on the brain’s reward systems, so they change not only appetite but also the pleasure of eating, its social role and possibly the motivation to drink alcohol. Experimental studies show that weight loss achieved with medication carries a stigma of its own, rooted in the belief that the patient has taken a “shortcut”. Use and misuse of GLP-1 receptor agonists are considerably more common among people with eating disorders. Controlled studies do not confirm a causal link with depression or suicidal ideation, but pharmacovigilance signals call for attention. Weight regain after discontinuation, aesthetic pressure and rare visual complications are discussed, together with a case from the authors’ own practice. Practical implications for clinical practice are proposed.
References
Downloads
Published
License
Copyright (c) 2026 E-Journal VFU

This work is licensed under a Creative Commons Attribution 4.0 International License.